152 related articles for article (PubMed ID: 8091742)
21. Determination of the inactivation kinetics of hepatitis A virus in human plasma products using a simple TCID50 assay.
Barrett PN; Meyer H; Wachtel I; Eibl J; Dorner F
J Med Virol; 1996 May; 49(1):1-6. PubMed ID: 8732864
[TBL] [Abstract][Full Text] [Related]
22. Absence of hepatitis A virus transmission by high-purity solvent detergent treated coagulation factor concentrates in Scottish haemophiliacs.
Watson HG; Ludlam CA; McOmish F; Dennis R; Hart H; Simmonds P
Br J Haematol; 1995 Jan; 89(1):214-6. PubMed ID: 7833268
[TBL] [Abstract][Full Text] [Related]
23. Distribution of a bovine spongiform encephalopathy-derived agent over ion-exchange chromatography used in the preparation of concentrates of fibrinogen and factor VIII.
Foster PR; Griffin BD; Bienek C; McIntosh RV; MacGregor IR; Somerville RA; Steele PJ; Reichl HE
Vox Sang; 2004 Feb; 86(2):92-9. PubMed ID: 15023177
[TBL] [Abstract][Full Text] [Related]
24. The outbreak of hepatitis A in Italian patients with hemophilia: facts and fancies.
Mannucci PM; Santagostino E; Di Bona E; Gentili G; Ghirardini A; Schiavoni M; Mele A
Vox Sang; 1994; 67 Suppl 1():31-5. PubMed ID: 8091734
[TBL] [Abstract][Full Text] [Related]
25. Hepatitis A virus infection among the hemophilia population at the Bonn Hemophilia Center.
Brackmann HH; Oldenburg J; Eis-Hübinger AM; Gerritzen A; Hammerstein U; Hanfland P
Vox Sang; 1994; 67 Suppl 1():3-7; discussion 8. PubMed ID: 8091733
[TBL] [Abstract][Full Text] [Related]
26. Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100 degrees C.
Dichtelmüller H; Rudnick D; Breuer B; Kotitschke R; Kloft M; Darling A; Watson E; Flehmig B; Lawson S; Frösner G
Biologicals; 1996 Jun; 24(2):125-30. PubMed ID: 8889059
[TBL] [Abstract][Full Text] [Related]
27. Progress in purification of virus-inactivated factor VIII concentrates. Three generations of solvent/detergent treated plasma derivatives.
Schwinn H; Smith A; Wolter D
Arzneimittelforschung; 1989 Oct; 39(10):1302-5. PubMed ID: 2514695
[TBL] [Abstract][Full Text] [Related]
28. Posttransfusion hepatitis type A.
Hollinger FB; Khan NC; Oefinger PE; Yawn DH; Schmulen AC; Dreesman GR; Melnick JL
JAMA; 1983 Nov; 250(17):2313-7. PubMed ID: 6313973
[TBL] [Abstract][Full Text] [Related]
29. Hepatitis A virus transmission by blood products in the United States. Transfusion Safety Study Group.
Mosley JW; Nowicki MJ; Kasper CK; Donegan E; Aledort LM; Hilgartner MW; Operskalski EA
Vox Sang; 1994; 67 Suppl 1():24-8. PubMed ID: 8091731
[TBL] [Abstract][Full Text] [Related]
30. A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool.
Chudy M; Budek I; Keller-Stanislawski B; McCaustland KA; Neidhold S; Robertson BH; Nübling CM; Seitz R; Löwer J
J Med Virol; 1999 Feb; 57(2):91-9. PubMed ID: 9892390
[TBL] [Abstract][Full Text] [Related]
31. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
32. Assessment of needs for plasma for fractionation in Europe.
Burckhardt JJ
Biologicals; 1999 Dec; 27(4):337-41. PubMed ID: 10686061
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of hepatitis A virus in plasma products by vapor heating.
Barrett PN; Meyer H; Wachtel I; Eibl J; Dorner F
Transfusion; 1997 Feb; 37(2):215-20. PubMed ID: 9051099
[TBL] [Abstract][Full Text] [Related]
34. Non-enveloped viruses transmitted by blood and blood products.
Robertson BH; Erdman DD
Dev Biol (Basel); 2000; 102():29-35. PubMed ID: 10794088
[TBL] [Abstract][Full Text] [Related]
35. Pasteurized, monoclonal antibody factor VIII concentrate: establishing a new standard for purity and viral safety of plasma-derived concentrates.
Goldsmith JC
Blood Coagul Fibrinolysis; 2000 Mar; 11(2):203-15. PubMed ID: 10759015
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis A virus infections associated with clotting factor concentrate in the United States.
Soucie JM; Robertson BH; Bell BP; McCaustland KA; Evatt BL
Transfusion; 1998 Jun; 38(6):573-9. PubMed ID: 9661691
[TBL] [Abstract][Full Text] [Related]
37. Inactivation of hepatitis A virus by heat treatment in aqueous solution.
Murphy P; Nowak T; Lemon SM; Hilfenhaus J
J Med Virol; 1993 Sep; 41(1):61-4. PubMed ID: 8228940
[TBL] [Abstract][Full Text] [Related]
38. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
39. [Virus in hemophilia: current status and future perspectives].
Aguilar C; Félix Lucía J
Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
[No Abstract] [Full Text] [Related]
40. Improvement of virus safety of an antihemophilc factor IX by virus filtration process.
Kim IS; Choi YW; Kang Y; Sung HM; Sohn KW; Kim YS
J Microbiol Biotechnol; 2008 Jul; 18(7):1317-25. PubMed ID: 18667862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
